InventisBio Co., Limited (SHA:688382)
China · Delayed Price · Currency is CNY 19.60
+0.34 (1.77%)
Sep 8, 2026, 4:00 PM EDT
InventisBio Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 71.44 | 37.29 | 168.79 | 185.53 | - | - | |
Revenue Growth | -58.72% | -77.91% | -9.02% | - | - | - |
Cost of Revenue | 5.5 | 5.02 | 3.92 | - | - | - |
Gross Profit | 65.95 | 32.27 | 164.87 | 185.53 | - | - |
Selling, General & Admin | 39.75 | 45.26 | 52.5 | 60.85 | 57.96 | 47.71 |
Research & Development | 395.05 | 325.79 | 384.35 | 442.91 | 461.49 | 315.04 |
Other Operating Expenses | 8.73 | 0.11 | 0.09 | 0.12 | -0 | 0.05 |
Operating Expenses | 439.7 | 383.76 | 445.82 | 513.18 | 519.44 | 362.8 |
Operating Income | -373.75 | -351.49 | -280.95 | -327.65 | -519.44 | -362.8 |
Interest Expense | -0.91 | -0.84 | -0.66 | -0.83 | -1.03 | -1.19 |
Interest & Investment Income | 24.78 | 25.89 | 30.02 | 40.45 | 17.38 | 12.76 |
Currency Exchange Gain (Loss) | -1.31 | -1.39 | 1.56 | 1.18 | 19.99 | -11.33 |
Other Non Operating Income (Expenses) | -0.15 | -0.11 | -0.11 | -0.27 | -0.2 | -0.21 |
EBT Excluding Unusual Items | -351.34 | -327.94 | -250.14 | -287.12 | -483.31 | -362.76 |
Gain (Loss) on Sale of Investments | 2.28 | 2.49 | 1.3 | - | - | - |
Gain (Loss) on Sale of Assets | -0.07 | - | 0.08 | - | - | 0 |
Other Unusual Items | 14.66 | 8.82 | 8.57 | 3.15 | -0.18 | 4.85 |
Pretax Income | -334.48 | -316.63 | -240.2 | -283.98 | -483.49 | -357.91 |
Income Tax Expense | 0.04 | 0.24 | - | - | - | - |
Net Income | -334.51 | -316.87 | -240.2 | -283.98 | -483.49 | -357.91 |
Net Income to Common | -334.51 | -316.87 | -240.2 | -283.98 | -483.49 | -357.91 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 577 | 576 | 572 | 575 | 509 | 459 |
Shares Outstanding (Diluted) | 577 | 576 | 572 | 575 | 509 | 459 |
Shares Change | 1.86% | 0.73% | -0.53% | 12.97% | 10.91% | -0.25% |
EPS (Basic) | -0.58 | -0.55 | -0.42 | -0.49 | -0.95 | -0.78 |
EPS (Diluted) | -0.58 | -0.55 | -0.42 | -0.49 | -0.95 | -0.78 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -243.44 | -162.36 | -249.53 | -314.04 | -484.59 | -278.59 |
Free Cash Flow Per Share | -0.42 | -0.28 | -0.44 | -0.55 | -0.95 | -0.61 |
Gross Margin | 92.31% | 86.54% | 97.67% | 100.00% | - | - |
Operating Margin | -523.13% | -942.59% | -166.45% | -176.61% | - | - |
Profit Margin | -468.21% | -849.74% | -142.31% | -153.06% | - | - |
Free Cash Flow Margin | -340.73% | -435.41% | -147.84% | -169.27% | - | - |
EBITDA | -369.17 | -346.58 | -275.16 | -322.31 | -514.77 | -360.15 |
EBITDA Margin | - | - | -163.02% | -173.73% | - | - |
D&A For EBITDA | 4.58 | 4.9 | 5.79 | 5.34 | 4.68 | 2.64 |
EBIT | -373.75 | -351.49 | -280.95 | -327.65 | -519.44 | -362.8 |
EBIT Margin | - | - | -166.45% | -176.61% | - | - |
Revenue as Reported | 71.44 | 37.29 | 168.79 | 185.53 | - | - |